University of Cambridge > > Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer > Cancer and ageing: Rival demons?

Cancer and ageing: Rival demons?

Add to your list(s) Download to your calendar using vCal

  • UserJudith Campisi, Buck Institute for Research on Ageing and Lawrence Berkeley National Laboratory World_link
  • ClockThursday 21 November 2019, 13:00-14:00
  • HouseCRUK CI Lecture Theatre.

If you have a question about this talk, please contact Kate Davenport.

Cancer is primarily a disease of ageing, similar to many other age-related pathologies ranging from sarcopenia to neurodegeneration. In contrast to many age-related diseases, which are loss-of-function in nature, cancer can be considered a gain-of-function disease because cancer cells must acquire new properties, generally by somatic mutation, in order to develop into a lethal tumor. Given that potentially oncogenic mutations occur throughout life, why do most cancers take decades to develop? One answer is there are powerful tumor suppressive mechanisms, selected throughout evolution, that keep cancer at bay for approximately half the mammalian life span. One of these tumor suppressive mechanisms is a cell fate decision termed cellular senescence. Cells undergo senescence in response to many types of stress or damage, including potentially oncogenic mutations. Senescent cells arrest proliferation, essentially irreversibly, and develop a complex senescence-associated secretory phenotype (SASP) that includes many inflammatory cytokines and chemokines, growth factors, proteases and bioactive metabolites, including lipids. Senescent cells increase with age in most, if not all, mammalian tissues, and are present at higher numbers in many diseased, compared to age-matched non-diseased, tissues. There is now mounting evidence that senescent cells, and particularly their SAS Ps, are prime drivers of many age-related pathologies, including, ironically, late-life cancer. Further, many genotoxic and cytotoxic anti-cancer drugs induce senescence in both tumor and normal cells, suggesting that senescent cells might be responsible for the premature aging phenotypes that commonly develop in cancer patients treated with certain anti-cancer therapies. Mouse models, and a new class of drugs that selectively kill senescent cells, give hope that the balance between tumor suppression and aging can be tipped to reduce the incidence of age-related cancer and extend health span.

This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity